NCT06528171 Covid-19 Long Immunité IMagerie (CLIIM)
| NCT ID | NCT06528171 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Nice |
| Condition | COVID Long-Haul |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-12-06 |
| Primary Completion | 2028-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2024-12-06 with a primary completion date of 2028-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Covid-long pathology affects a large number of patients, and represents a major medical, economic and societal challenge. To date, we have no objective criterion for a definitive diagnosis, nor any predictive tool for monitoring the evolution of Covid-long. Based on recruitment from the infectious diseases department of Nice University Hospital, the investigator's team wants to conduct an innovative pathophysiological study to better define the disease and identify specific biomarkers that could subsequently be used as a diagnostic tool for Covid-long. 120 participants will be initially included for the model learning phase: 60 controls in the CL- cohort and 60 patients in the CL+ cohort. Then 80 patients (40 CL+ and 40 Cl-) will be enrolled for the model validation phase.
Eligibility Criteria
FOR CL+ PATIENTS Inclusion Criteria: * Case definition in line with WHO Delphi process Exclusion Criteria: * History of chronic fatigue syndrome diagnosed before or after Covid. * History of progressive psychiatric pathology. * History of acute Covid requiring admission to intensive care and mechanical ventilation. * No social security affiliation. FOR CONTROL (CL-) Inclusion Criteria: * History of acute COVID-19, mild, moderate or severe (episode at least 3 months at the time of inclusion). * Absence of persistent symptoms more than 3 months after first Covid symptoms (or mild not affecting daily activities). Exclusion Criteria: * History of progressive psychiatric pathology. * History of acute Covid requiring admission to intensive care and mechanical ventilation. * No social security affiliation. * Pregnant or breast-feeding.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06528171 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying COVID Long-Haul. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06528171 currently recruiting?
Yes, NCT06528171 is actively recruiting participants. Contact the research team at carles.m@chu-nice.fr for enrollment information.
Where is the NCT06528171 trial being conducted?
This trial is being conducted at Nice, France.
Who is sponsoring the NCT06528171 clinical trial?
NCT06528171 is sponsored by Centre Hospitalier Universitaire de Nice. The trial plans to enroll 200 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.